Active Pharmaceutical Ingredient/ API Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormone, Biosimilar) Drug (OTC, Rx), Therapy, and Region - Global Forecast to 2024

Table of Contents

1.... INTRODUCTION

1.1            OBJECTIVES OF THE STUDY
1.2            MARKET DEFINITION
1.3            MARKET SCOPE
1.3.1             MARKETS COVERED.. 27
1.3.2             YEARS CONSIDERED FOR THE STUDY
1.4            CURRENCY
1.5            LIMITATIONS. 29
1.6            STAKEHOLDERS

2.... RESEARCH METHODOLOGY

2.1            RESEARCH DATA
2.1.1             SECONDARY SOURCES. 31
2.1.1.1           KEY DATA FROM SECONDARY SOURCES
2.1.2             PRIMARY SOURCES. 32
2.1.2.1           KEY DATA FROM PRIMARY SOURCES
2.1.2.2           KEY INDUSTRY INSIGHTS
2.2            MARKET SIZE ESTIMATION
2.3            MARKET BREAKDOWN AND DATA TRIANGULATION
2.4            MARKET SHARE ESTIMATION
2.5            ASSUMPTIONS FOR THE STUDY

3.... EXECUTIVE SUMMARY

4.... PREMIUM INSIGHTS

4.1            ACTIVE PHARMACEUTICAL INGREDIENTS: MARKET OVERVIEW
4.2            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE
4.3            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER
4.4            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE  OF SYNTHESIS
4.5            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE  OF DRUG
4.6            GEOGRAPHIC SNAPSHOT: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

5.... MARKET OVERVIEW

5.1            INTRODUCTION
5.2            MARKET DYNAMICS
5.2.1             DRIVERS
5.2.1.1           INCREASING INCIDENCE OF CHRONIC DISEASES
5.2.1.2           TECHNOLOGICAL ADVANCEMENTS IN API MANUFACTURING
5.2.1.3           GROWING IMPORTANCE OF GENERICS
5.2.1.4           INCREASING UPTAKE OF BIOPHARMACEUTICALS
5.2.1.5           GROWING ADOPTION OF ARTIFICIAL INTELLIGENCE-BASED TOOLS FOR DRUG DISCOVERY
5.2.1.6           ADOPTION OF ORGAN-ON-CHIP MODELS IN DRUG DEVELOPMENT
5.2.1.7           GROWING FOCUS ON PRECISION MEDICINE
5.2.1.8           GROWING INVESTMENTS IN REAL-WORLD EVIDENCE BY PHARMACEUTICAL COMPANIES
5.2.2             RESTRAINTS
5.2.2.1           UNFAVORABLE DRUG PRICE CONTROL POLICIES ACROSS VARIOUS COUNTRIES
5.2.2.2           INCREASING PENETRATION OF COUNTERFEIT DRUGS
5.2.3             OPPORTUNITIES
5.2.3.1           EMERGING BIOSIMILARS MARKET
5.2.3.2           HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENTS
5.2.3.3           EMERGING MARKETS
5.2.3.4           EMERGING TECHNOLOGIES
5.2.4             CHALLENGES
5.2.4.1           PRODUCT DIFFERENTIATION - A MAJOR CONCERN FOR API MANUFACTURERS. 57
5.2.4.2           HIGH MANUFACTURING COSTS

6.... ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE

6.1            INTRODUCTION
6.2            INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS
6.2.1             GROWING NUMBER OF NEW MOLECULAR ENTITIES GAINING REGULATORY APPROVAL TO DRIVE MARKET GROWTH
6.3            GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS
6.3.1             GOVERNMENT INITIATIVES SUPPORTING THE ADOPTION OF GENERIC DRUGS TO BOOST MARKET GROWTH

7.... ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY TYPE OF MANUFACTURER

7.1            INTRODUCTION
7.2            CAPTIVE API MANUFACTURERS
7.2.1             HIGH MANUFACTURING FLEXIBILITY AND ASSURANCE OF PRODUCT QUALITY HAVE DRIVEN FOCUS ON CAPTIVE MANUFACTURING
7.3            MERCHANT API MANUFACTURERS
7.3.1             MERCHANT API MANUFACTURERS MARKET, BY TYPE
7.3.1.1           MERCHANT INNOVATIVE API MANUFACTURERS
7.3.1.1.1           IMPENDING PATENT EXPIRIES AND INCREASING COSTS OF INNOVATIVE DRUGS MAY RESTRAIN MARKET GROWTH
7.3.1.2           MERCHANT GENERIC API MANUFACTURERS
7.3.1.2.1           LOW MANUFACTURING COST OF GENERICS LIKELY TO DRIVE THE GROWTH OF THIS SEGMENT

7.3.2             MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS
7.3.2.1           MERCHANT SYNTHETIC API MANUFACTURERS
7.3.2.1.1           NEED FOR SPECIALIZED MANUFACTURING CAPABILITIES HAS RESULTED IN EXPANSION AMONG MARKET PLAYERS IN THIS SEGMENT
7.3.2.2           MERCHANT BIOTECH API MANUFACTURERS
7.3.2.2.1           COMPLEXITY OF MANUFACTURING BIOTECH APIS HAS DRIVEN FOCUS ON PARTNERSHIPS BETWEEN COMPANIES AND CMOS

8.... ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY TYPE OF SYNTHESIS

8.1            INTRODUCTION
8.2            SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS
8.2.1             SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY TYPE
8.2.1.1           INNOVATIVE SYNTHETIC APIS
8.2.1.1.1           THE HIGH VALUE OF INNOVATIVE APIS TO DRIVE THE GROWTH OF THIS SEGMENT
8.2.1.2           GENERIC SYNTHETIC APIS
8.2.1.2.1           INITIATIVES TO PROMOTE THE PENETRATION OF GENERICS TO BRING DOWN HEALTHCARE COSTS—A MAJOR GROWTH DRIVER
8.3            BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS
8.3.1             BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE
8.3.1.1           INNOVATIVE BIOTECH APIS
8.3.1.1.1           GROWING DEMAND FOR INNOVATIVE BIOPHARMACEUTICALS TO DRIVE THE MARKET FOR THIS SEGMENT
8.3.1.2           GENERIC BIOTECH APIS
8.3.1.2.1           INCREASING DEMAND FOR BIOSIMILAR DRUGS DUE TO THEIR COST-EFFECTIVENESS TO DRIVE THE GROWTH OF THIS SEGMENT
8.3.2             BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY PRODUCT
8.3.2.1           MONOCLONAL ANTIBODIES
8.3.2.1.1           GROWING APPLICATIONS OF ANTIBODY-DRUG CONJUGATES IN THE TREATMENT OF CANCER TO DRIVE THE GROWTH OF THIS SEGMENT
8.3.2.2           HORMONES & GROWTH FACTORS
8.3.2.2.1           THE GROWING INCIDENCE OF HORMONAL DISORDERS TO DRIVE THE MARKET FOR THIS SEGMENT
8.3.2.3           CYTOKINES
8.3.2.3.1           INTERFERONS AND INTERLEUKINS BOOST THE IMMUNE SYSTEM AND HAVE IMPORTANT APPLICATIONS IN CANCER TREATMENT
8.3.2.4           FUSION PROTEINS
8.3.2.4.1           GROWING APPLICATIONS OF FC FUSION PROTEINS IN BIOPHARMACEUTICALS TO DRIVE THE GROWTH OF THIS SEGMENT
8.3.2.5           RECOMBINANT VACCINES
8.3.2.5.1           GROWING PREVALENCE OF INFECTIOUS DISEASES HAS BOOSTED VACCINE DEVELOPMENT—A POSITIVE INDICATOR OF GROWTH
8.3.2.6           THERAPEUTIC ENZYMES
8.3.2.6.1           GROWING SIGNIFICANCE OF ENZYMES IN THERAPIES FOR CANCER AND PAIN MANAGEMENT TO DRIVE THE GROWTH OF THIS SEGMENT
8.3.2.7           BLOOD FACTORS
8.3.2.7.1           GROWING INCIDENCE OF HEMOPHILIA TO DRIVE THE GROWTH OF THIS SEGMENT
8.3.3             BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY EXPRESSION SYSTEM
8.3.3.1           MAMMALIAN EXPRESSION SYSTEMS
8.3.3.1.1           ABILITY OF THESE SYSTEMS TO CARRY POST-TRANSLATIONAL MODIFICATION TO DRIVE THE MARKET FOR THIS SEGMENT
8.3.3.2           MICROBIAL EXPRESSION SYSTEMS
8.3.3.2.1           ABILITY OF THESE EXPRESSION SYSTEMS TO PROVIDE HIGH EXPRESSION LEVELS OF PROTEINS TO DRIVE THE MARKET FOR THIS SEGMENT
8.3.3.3           YEAST EXPRESSION SYSTEMS
8.3.3.3.1           ADVANTAGES SUCH AS EFFICIENT PROTEIN SECRETION, SIMPLE PURIFICATION, AND ENDOTOXIN-FREE PRODUCTS TO BOOST DEMAND
8.3.3.4           INSECT EXPRESSION SYSTEMS
8.3.3.4.1           EFFICIENT POST-TRANSLATIONAL MODIFICATIONS PROVIDED BY THESE SYSTEMS TO BOOST THEIR DEMAND
8.3.3.5           OTHER EXPRESSION SYSTEMS

9.... ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY TYPE OF DRUG

9.1            INTRODUCTION
9.2            PRESCRIPTION DRUGS
9.2.1             GROWING DISEASE PREVALENCE IS EXPECTED TO DRIVE THE PRESCRIPTION DRUGS MARKET
9.3            OVER-THE-COUNTER DRUGS
9.3.1             SALES OF OTC DRUGS HAVE RISEN DUE TO INNOVATIONS, PROMOTION OF SELF-MEDICATION, AND INCREASED ACCESS
9.4            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY
9.4.1             LOW-TO-MODERATE POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS
9.4.2             POTENT-TO-HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENTS

10.. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,  BY THERAPEUTIC APPLICATION

10.1          INTRODUCTION
10.2          COMMUNICABLE DISEASES
10.2.1           GLOBAL HEALTH IMPACT OF COMMUNICABLE DISEASES AND INCREASING ANTIMICROBIAL RESISTANCE—KEY MARKET DRIVERS
10.3          ONCOLOGY
10.3.1           INCREASE IN GLOBAL SPENDING ON CANCER MEDICATION TO BOOST THE MARKET FOR THIS SEGMENT
10.4          PAIN MANAGEMENT
10.4.1           INCREASING DEMAND FOR INNOVATIVE AND ADVANCED PAIN MEDICATIONS IS A MAJOR GROWTH DRIVER FOR THIS MARKET

10.5          CARDIOVASCULAR DISEASES
10.5.1           GROWING INCIDENCE OF CARDIOVASCULAR DISEASES OWING TO SEDENTARY LIFESTYLES IS A MAJOR GROWTH DRIVER
10.6          DIABETES
10.6.1           HIGH GLOBAL PREVALENCE OF DIABETES TO DRIVE THE GROWTH OF THIS SEGMENT
10.7          RESPIRATORY DISEASES
10.7.1           HIGH GLOBAL PREVALENCE OF RESPIRATORY DISEASES TO DRIVE THE GROWTH OF THIS SEGMENT
10.8          OTHER THERAPEUTIC APPLICATIONS

11.. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION

11.1          INTRODUCTION
11.2          NORTH AMERICA
11.2.1           US
11.2.1.1         INCREASING EXPENDITURE ON MEDICINE IS EXPECTED TO DRIVE THE APIS MARKET IN THE US
11.2.2           CANADA
11.2.2.1         SUPPORT FROM GOVERNMENT ORGANIZATIONS IS DRIVING THE GROWTH OF THE APIS MARKET IN CANADA
11.3          EUROPE
11.3.1           GERMANY
11.3.1.1         GERMANY TO DOMINATE THE MARKET IN EUROPE
11.3.2           FRANCE
11.3.2.1         EMERGENCE OF PHARMERGING MARKETS IN ASIA MAY HINDER MARKET GROWTH IN FRANCE
11.3.3           UK
11.3.3.1         GROWING ADOPTION OF GENERICS WILL DRIVE THE GROWTH OF THE UK MARKET
11.3.4           ITALY
11.3.4.1         ITALY’S SHARE IN THE GLOBAL MERCHANT APIS MARKET IS EXPECTED TO REMAIN STABLE OVER THE FORECAST PERIOD
11.3.5           SPAIN
11.3.5.1         SPANISH MARKET HAS BEEN TYPICALLY DOMINATED BY BRANDED DRUGS
11.3.6           REST OF EUROPE
11.4          ASIA
11.4.1           JAPAN
11.4.1.1         JAPANESE GOVERNMENT AIMS TO BOOST THE USE OF GENERICS BY 2020
11.4.2           CHINA
11.4.2.1         GOVERNMENT POLICIES TO INCREASE MEDICINE ACCESS AND AFFORDABILITY WILL SUPPORT MARKET GROWTH
11.4.3           INDIA
11.4.3.1         INDIA IS A LEADING PRODUCER OF GENERICS

11.4.4           SOUTH KOREA
11.4.4.1         GOVERNMENT INITIATIVES TO INTRODUCE FULL MEDICAL COVERAGE FOR MAJOR CHRONIC DISEASES LIKELY TO DRIVE THIS MARKET
11.4.5           REST OF ASIA
11.5          REST OF THE WORLD

12.. COMPETITIVE LANDSCAPE

12.1          OVERVIEW
12.2          MARKET PLAYER RANKING
12.3          COMPETITIVE LEADERSHIP MAPPING
12.3.1           VANGUARDS
12.3.2           DYNAMIC DIFFERENTIATORS
12.3.3           INNOVATORS
12.3.4           EMERGING PLAYERS. 204
12.4          COMPETITIVE SITUATION AND TRENDS
12.4.1           PRODUCT LAUNCHES. 206
12.4.2           EXPANSIONS
12.4.3           ACQUISITIONS
12.4.4           OTHER STRATEGIES. 207

13.. COMPANY PROFILES

(BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, MNM VIEW)*
13.1          PFIZER, INC.
13.2          NOVARTIS AG.. 212
13.3          SANOFI
13.4          BOEHRINGER INGELHEIM
13.5          BRISTOL-MYERS SQUIBB
13.6          TEVA PHARMACEUTICAL INDUSTRIES LTD.
13.7          ELI LILLY AND COMPANY
13.8          GLAXOSMITHKLINE PLC
13.9          MERCK & CO., INC.
13.10        ABBVIE INC. 238
13.11        F. HOFFMANN-LA ROCHE
13.12        ASTRAZENECA. 244
*DETAILS ON BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, MNM VIEW MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.

14.. APPENDIX

List of TableS

TABLE 1              Indicative list of drugs Going Generic in 2018
TABLE 2              Indicative list of biologics that gained regulatory approval 
in the US in 2017–2018
TABLE 3              Indicative list of Biosimilars that gained us regulatory
approval in 2018
TABLE 4              active pharmaceutical ingredients MARKET, BY type,
2017–2024 (USD billion)
TABLE 5              Indicative list of new molecular entities that gained US FDA approval in 2018
TABLE 6              List of Major drugs set to lose patent protection in 2018
TABLE 7              innovative active pharmaceutical ingredients MARKET,
BY REGION,  2017–2024 (USD billion)
TABLE 8              generic active pharmaceutical ingredients MARKET, BY REGION, 
2017–2024 (USD billion)
TABLE 9              active pharmaceutical ingredients MARKET, BY type of MANUFACTURER,  2017–2024 (USD billion)
TABLE 10            captive API manufacturers MARKET, BY REGION, 2017–2024 (USD billion)
TABLE 11            list of significant CMO/CDMO facility expansions
TABLE 12            MERCHANT API MANUFACTURERs MARKET, BY REGION,
2017–2024 (USD billion)
TABLE 13            merchant API manufacturers MARKET, BY type, 2017–2024 (USD billion)
TABLE 14            merchant innovative API manufacturers MARKET, BY REGION, 
2017–2024 (USD billion)
TABLE 15            merchant generic API manufacturers MARKET, BY REGION, 
2017–2024 (USD billion)
TABLE 16            merchant API manufacturers MARKET, BY type of synthesis 
2017–2024 (USD billion)
TABLE 17            merchant synthetic api manufacturers MARKET, BY REGION, 
2017–2024 (USD billion)
TABLE 18            merchant biotech api manufacturers MARKET, BY REGION, 
2017–2024 (USD billion)
TABLE 19            active pharmaceutical ingredients MARKET, BY type OF SYNTHESIS, 
2017–2024 (USD billion)
TABLE 20            synthetic active pharmaceutical ingredients MARKET, BY REGION, 
2017–2024 (USD billion)
TABLE 21            synthetic active pharmaceutical ingredients MARKET, BY type 
2017–2024 (USD billion)
TABLE 22            innovative synthetic active pharmaceutical ingredients MARKET,
BY REGION, 2017–2024 (USD billion)
TABLE 23            generic synthetic active pharmaceutical ingredients MARKET,
BY REGION, 2017–2024 (USD billion)
TABLE 24            Top Selling Biologics (2018)
TABLE 25            biotech active pharmaceutical ingredients MARKET, BY REGION, 
2017–2024 (USD billion)
TABLE 26            biotech active pharmaceutical ingredients MARKET, BY type, 
2017–2024 (USD billion)
TABLE 27            innovative biotech active pharmaceutical ingredients MARKET,
BY REGION, 2017–2024 (USD billion)
TABLE 28            Indicative list of biosimilars that gained us FDA APPROVAL during
2017–2018
TABLE 29            generic biotech active pharmaceutical ingredients MARKET, 
BY REGION, 2017–2024 (USD billion)
TABLE 30            Biotech active pharmaceutical ingredients MARKET, BY product 
2017–2024 (USD billion)
TABLE 31            indicative list of MONOCLONAL antibodies that received FDa approval
in 2018
TABLE 32            Biotech active pharmaceutical ingredients MARKET for monoclonal antibodies, BY REGION, 2017–2024 (USD billion)
TABLE 33            Biotech active pharmaceutical ingredients MARKET for hormones & growth factors, BY REGION, 2017–2024 (USD billion)
TABLE 34            Biotech active pharmaceutical ingredients MARKET for cytokines,
BY REGION, 2017–2024 (USD billion)
TABLE 35            Biotech active pharmaceutical ingredients MARKET for fusion proteins,  BY REGION, 2017–2024 (USD billion)
TABLE 36            Biotech active pharmaceutical ingredients MARKET for recombinant vaccines, BY REGION, 2017–2024 (USD million)
TABLE 37            Biotech active pharmaceutical ingredients MARKET for therapeutic enzymes, BY REGION, 2017–2024 (USD million)
TABLE 38            Biotech active pharmaceutical ingredients MARKET for blood factors,  BY REGION, 2017–2024 (USD million)
TABLE 39            biotech active pharmaceutical ingredients MARKET, BY expression system, 2017–2024 (USD billion)
TABLE 40            biotech active pharmaceutical ingredients MARKET for Mammalian Expression Systems, BY REGION, 2017–2024 (USD billion)
TABLE 41            biotech active pharmaceutical ingredients MARKET for microbial Expression Systems, BY REGION, 2017–2024 (USD billion)
TABLE 42            biotech active pharmaceutical ingredients MARKET for yeast Expression Systems, BY REGION, 2017–2024 (USD billion)
TABLE 43            biotech active pharmaceutical ingredients MARKET for insect Expression Systems, BY REGION, 2017–2024 (USD billion)
TABLE 44            biotech active pharmaceutical ingredients MARKET for other expression systems, BY REGION, 2017–2024 (USD million)
TABLE 45            active pharmaceutical ingredients MARKET, BY type of drug, 
2017–2024 (USD Billion)
TABLE 46            prescription drugs MARKET, BY REGION, 2017–2024 (USD Billion)
TABLE 47            over-the-counter drugs MARKET, BY REGION, 2017-2024 (USD Billion)
TABLE 48            active pharmaceutical ingredients MARKET, BY potency, 
2017–2024 (USD Billion)
TABLE 49            active pharmaceutical ingredients MARKET, BY therapeutic application,  2017–2024 (USD billion)
TABLE 50            Indicative list of US fda-approved drugs for communicable diseases (2018)
TABLE 51            active pharmaceutical INGREDIENTS market for communicable diseases,  BY REGION, 2017–2024 (USD billion)
TABLE 52            Indicative list of US fda-approved drugs for oncology (2018)
TABLE 53            active pharmaceutical INGREDIENTS market for oncology, 
BY REGION, 2017–2024 (USD billion)
TABLE 54            Indicative list of US fda-approved drugs for pain management (2018)
TABLE 55            active pharmaceutical ingredients market for pain management,
BY REGION, 2017–2024 (USD billion)
TABLE 56            active pharmaceutical ingredients market for cardiovascular diseases,  BY REGION, 2017–2024 (USD billion)
TABLE 57            active pharmaceutical ingredients market for diabetes, BY REGION,  2017–2024 (USD billion)
TABLE 58            active pharmaceutical ingredients market for respiratory diseases,  BY REGION, 2017–2024 (USD billion)
TABLE 59            active pharmaceutical ingredients market for other therapeutic applications, BY REGION, 2017–2024 (USD billion)
TABLE 60            Active pharmaceutical ingredients Market, By Region, 
2017–2024 (USD billion)
TABLE 61            North America: Active pharmaceutical ingredients Market, 
By Country, 2017–2024 (USD BILLION)
TABLE 62            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS Market, 
by type, 2017–2024 (USD BILLION)
TABLE 63            North America: active pharmaceutical ingredients Market,
by type of manufacturer, 2017–2024 (USD BILLION)
TABLE 64            North America: MERCHANT API manufacturers market, by type, 
2017–2024 (USD BILLION)
TABLE 65            North America: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017–2024 (USD BILLION)
TABLE 66            North America: active pharmaceutical ingredients Market,
by Type of synthesis, 2017–2024 (USD BILLION)
TABLE 67            North America: synthetic Active pharmaceutical ingredients market, by type, 2017–2024 (USD BILLION)
TABLE 68            North America: biotech Active pharmaceutical ingredients market,
by type, 2017–2024 (USD BILLION)
TABLE 69            North America: biotech Active pharmaceutical ingredients market, 
by product, 2017–2024 (USD BILLION)
TABLE 70            North America: Active pharmaceutical ingredients Market,
by type of drug, 2017–2024 (USD BILLION)
TABLE 71            North america: Active pharmaceutical ingredients Market,
by potency,  2017–2024 (USD BILLION)
TABLE 72            North america: Active pharmaceutical ingredients Market,
by therapeutic application, 2017–2024 (USD BILLION)
TABLE 73            indicative list of recent fda approvals for drug delivery products
TABLE 74            US: ACTIVE PHARMACEUTICAL INGREDIENTS Market, by type, 
2017–2024 (USD BILLION)
TABLE 75            US: active pharmaceutical ingredients Market, by type of manufacturer, 2017–2024 (USD BILLION) 122
TABLE 76            US: MERCHANT API manufacturers market, by type,
2017–2024 (USD BILLION)
TABLE 77            US: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 
2017–2024 (USD BILLION)
TABLE 78            US: active pharmaceutical ingredients Market, by Type of synthesis,  2017–2024 (USD BILLION)
TABLE 79            US: synthetic Active pharmaceutical ingredients market, by type,  2017–2024 (USD BILLION)
TABLE 80            US: biotech Active pharmaceutical ingredients market, by type, 
2017–2024 (USD BILLION)
TABLE 81            US: Active pharmaceutical ingredients Market, by type of drug, 
2017–2024 (USD BILLION)
TABLE 82            US: Active pharmaceutical ingredients Market, by potency, 
2017–2024 (USD BILLION)
TABLE 83            US: Active pharmaceutical ingredients Market, by therapeutic application, 2017–2024 (USD BILLION)
TABLE 84            CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS Market, by type, 
2017–2024 (USD BILLION)
TABLE 85            Canada: active pharmaceutical ingredients Market, by type of manufacturer, 2017–2024 (USD BILLION) 127
TABLE 86            canada: MERCHANT API manufacturers market, by type, 
2017–2024 (USD BILLION)
TABLE 87            canada: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS,  2017–2024 (USD BILLION)
TABLE 88            canada: active pharmaceutical ingredients Market, by Type of synthesis, 2017–2024 (USD BILLION)
TABLE 89            canada: synthetic Active pharmaceutical ingredients Market, by type,  2017–2024 (USD BILLION)
TABLE 90            canada: biotech Active pharmaceutical ingredients Market, by type,  2017–2024 (USD BILLION)
TABLE 91            Canada: Active pharmaceutical ingredients Market, by type of drug,  2017–2024 (USD BILLION)
TABLE 92            Canada: Active pharmaceutical ingredients Market, by potency, 
2017–2024 (USD BILLION)
TABLE 93            Canada: Active pharmaceutical ingredients Market, by therapeutic application, 2017–2024 (USD BILLION)
TABLE 94            Europe: Active pharmaceutical ingredients Market, By Country, 
2017–2024 (USD BILLION)
TABLE 95            europe: ACTIVE PHARMACEUTICAL INGREDIENTS Market, by type, 
2017–2024 (USD BILLION)
TABLE 96            europe: active pharmaceutical ingredients Market, by type of manufacturer, 2017–2024 (USD BILLION) 133
TABLE 97            europe: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 
2017–2024 (USD BILLION)
TABLE 98            europe: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS,  2017–2024 (USD BILLION)
TABLE 99            europe: active pharmaceutical ingredients Market,
by type of synthesis, 2017–2024 (USD BILLION)
TABLE 100          europe: synthetic Active pharmaceutical ingredients Market, 
by type, 2017–2024 (USD BILLION)
TABLE 101          europe: biotech Active pharmaceutical ingredients Market, 
by type, 2017–2024 (USD BILLION)
TABLE 102          europe: biotech Active pharmaceutical ingredients Market,
by product, 2017–2024 (USD BILLION)
TABLE 103          europe: Active pharmaceutical ingredients Market, by type of drug,  2017–2024 (USD BILLION)
TABLE 104          europe: Active pharmaceutical ingredients Market, by potency, 
2017–2024 (USD BILLION)
TABLE 105          europe: Active pharmaceutical ingredients Market, by therapeutic application, 2017–2024 (USD BILLION)
TABLE 106          Germany: ACTIVE PHARMACEUTICAL INGREDIENTS Market, by type, 
2017–2024 (USD bILLION)
TABLE 107          Germany: active pharmaceutical ingredients Market, by type
of manufacturer, 2017–2024 (USD bILLION)
TABLE 108          Germany: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 
2017–2024 (USD bILLION)
TABLE 109          Germany: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS,  2017–2024 (USD bILLION)
TABLE 110          Germany: active pharmaceutical ingredients Market,
by type of synthesis, 2017–2024 (USD bILLION)
TABLE 111          Germany: synthetic Active pharmaceutical ingredients Market,
by type,  2017–2024 (USD bILLION)
TABLE 112          Germany: biotech Active pharmaceutical ingredients Market,
by type,  2017–2024 (USD bILLION)
TABLE 113          Germany: Active pharmaceutical ingredients Market, by type of drug,  2017–2024 (USD bILLION)
TABLE 114          Germany: Active pharmaceutical ingredients Market, by potency,  2017–2024 (USD bILLION)
TABLE 115          Germany: Active pharmaceutical ingredients Market, by therapeutic application, 2017–2024 (USD bILLION)
TABLE 116          FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS Market, by type, 
2017–2024 (USD bILLION)
TABLE 117          FRANCE: active pharmaceutical ingredients Market, by type of manufacturer, 2017–2024 (USD bILLION) 143
TABLE 118          FRANCE: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 
2017–2024 (USD bILLION)
TABLE 119          FRANCE: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS,  2017–2024 (USD bILLION)
TABLE 120          FRANCE: active pharmaceutical ingredients Market, by Type of synthesis, 2017–2024 (USD bILLION)
TABLE 121          FRANCE: synthetic Active pharmaceutical ingredients Market,
by type,  2017–2024 (USD bILLION)
TABLE 122          FRANCE: biotech Active pharmaceutical ingredients Market, 
by type, 2017–2024 (USD bILLION)
TABLE 123          FRANCE: Active pharmaceutical ingredients Market, by type
of drug,  2017–2024 (USD bILLION)
TABLE 124          FRANCE: Active pharmaceutical ingredients Market, by potency, 
2017–2024 (USD bILLION)
TABLE 125          france: Active pharmaceutical ingredients Market, by therapeutic application, 2017–2024 (USD bILLION)
TABLE 126          UK: ACTIVE PHARMACEUTICAL INGREDIENTS Market, by type, 
2017–2024 (USD bILLION)
TABLE 127          UK: active pharmaceutical ingredients Market, by type of manufacturer, 2017–2024 (USD bILLION) 149
TABLE 128          UK: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2017–2024 (USD bILLION)
TABLE 129          UK: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 
2017–2024 (USD bILLION)
TABLE 130          UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS,  2017–2024 (USD bILLION)
TABLE 131          UK: synthetic Active pharmaceutical ingredients Market, by type,  2017–2024 (USD bILLION)
TABLE 132          UK: biotech Active pharmaceutical ingredients Market, by type, 
2017–2024 (USD bILLION)
TABLE 133          UK: Active pharmaceutical ingredients Market, by type of drug, 
2017–2024 (USD bILLION)
TABLE 134          UK: Active pharmaceutical ingredients Market, by potency, 
2017–2024 (USD bILLION)
TABLE 135          UK: Active pharmaceutical ingredients Market, by therapeutic application, 2017–2024 (USD bILLION)
TABLE 136          italy: ACTIVE PHARMACEUTICAL INGREDIENTS Market, by type, 
2017–2024 (USD bILLION)
TABLE 137          italy: active pharmaceutical ingredients Market, by type of  manufacturer, 2017–2024 (USD bILLION)
TABLE 138          italy: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2017–2024 (USD bILLION)
TABLE 139          italy: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS,  2017–2024 (USD bILLION)
TABLE 140          Italy: active pharmaceutical ingredients Market, by type of synthesis,  2017–2024 (USD bILLION)
TABLE 141          italy: synthetic Active pharmaceutical ingredients Market, by type,  2017–2024 (USD bILLION)
TABLE 142          italy: biotech Active pharmaceutical ingredients Market, by type,  2017–2024 (USD bILLION)
TABLE 143          Italy: Active pharmaceutical ingredients Market, by type of drug,  2017–2024 (USD bILLION)
TABLE 144          italy: Active pharmaceutical ingredients Market, by Potency, 
2017–2024 (USD bILLION)
TABLE 145          Italy: Active pharmaceutical ingredients Market, by therapeutic application, 2017–2024 (USD bILLION)
TABLE 146          spain: ACTIVE PHARMACEUTICAL INGREDIENTS Market, by type, 
2017–2024 (USD BILLION)
TABLE 147          spain: active pharmaceutical ingredients Market, by type of manufacturer, 2017–2024 (USD BILLION) 158
TABLE 148          spain: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2017–2024 (USD BILLION)
TABLE 149          spain: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS,  2017–2024 (USD BILLION)
TABLE 150          spain: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS,  2017–2024 (USD BILLION)
TABLE 151          spain: synthetic Active pharmaceutical ingredients Market, 
by type, 2017–2024 (USD BILLION)
TABLE 152          spain: biotech Active pharmaceutical ingredients Market,
by type,  2017–2024 (USD MILLION)
TABLE 153          spain: Active pharmaceutical ingredients Market, by type of drug,  2017–2024 (USD bILLION)
TABLE 154          spain: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 
2017–2024 (USD MILLION)
TABLE 155          spain: Active pharmaceutical ingredients Market, by therapeutic application, 2017–2024 (USD MILLION)
TABLE 156          RoE: ACTIVE PHARMACEUTICAL INGREDIENTS Market, by type, 
2017–2024 (USD bILLION)
TABLE 157          RoE: active pharmaceutical ingredients Market, by type of manufacturer, 2017–2024 (USD bILLION) 163
TABLE 158          RoE: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2017–2024 (USD bILLION)
TABLE 159          RoE: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 
2017–2024 (USD bILLION)
TABLE 160          RoE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS,  2017–2024 (USD bILLION)
TABLE 161          RoE: synthetic Active pharmaceutical ingredients Market, by type,  2017–2024 (USD bILLION)
TABLE 162          RoE: biotech Active pharmaceutical ingredients Market, by type, 
2017–2024 (USD bILLION)
TABLE 163          RoE: Active pharmaceutical ingredients Market, by type of drug, 
2017–2024 (USD bILLION)
TABLE 164          RoE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 
2017–2024 (USD bILLION)
TABLE 165          RoE: Active pharmaceutical ingredients Market, by therapeutic application, 2017–2024 (USD bILLION)
TABLE 166          asia: Active pharmaceutical ingredients Market, By Country, 
2017–2024 (USD bILLION)
TABLE 167          asia: ACTIVE PHARMACEUTICAL INGREDIENTS Market, by type, 
2017–2024 (USD bILLION)
TABLE 168          asia: active pharmaceutical ingredients Market, by type of manufacturer, 2017–2024 (USD bILLION) 168
TABLE 169          asia: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2017–2024 (USD BILLION)
TABLE 170          asia: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 
2017–2024 (USD bILLION)
TABLE 171          asia: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS,  2017–2024 (USD bILLION)
TABLE 172          asia: synthetic Active pharmaceutical ingredients Market,
by type,  2017–2024 (USD bILLION)
TABLE 173          asia: biotech Active pharmaceutical ingredients Market, by type, 
2017–2024 (USD bILLION)
TABLE 174          asia: biotech Active pharmaceutical ingredients Market, by product,  2017–2024 (USD MILLION)
TABLE 175          asia: Active pharmaceutical ingredients Market, by type of drug,  2017–2024 (USD biLLION)
TABLE 176          asia: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 
2017–2024 (USD bILLION)
TABLE 177          asia: Active pharmaceutical ingredients Market, by therapeutic application, 2017–2024 (USD bILLION)
TABLE 178          japan: ACTIVE PHARMACEUTICAL INGREDIENTS Market, by type, 
2017–2024 (USD bILLION)
TABLE 179          japan: active pharmaceutical ingredients Market, by type of manufacturer, 2017–2024 (USD bILLION) 173
TABLE 180          japan: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2017–2024 (USD bILLION)
TABLE 181          japan: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS,  2017–2024 (USD bILLION)
TABLE 182          japan: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS,  2017–2024 (USD bILLION)
TABLE 183          japan: synthetic Active pharmaceutical ingredients Market, 
by type, 2017–2024 (USD bILLION)

TABLE 184          japan: biotech Active pharmaceutical ingredients Market,
by type,  2017–2024 (USD bILLION)
TABLE 185          japan: Active pharmaceutical ingredients Market, by type of drug,  2017–2024 (USD bILLION)
TABLE 186          japan: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 
2017–2024 (USD bILLION)
TABLE 187          japan: Active pharmaceutical ingredients Market, by therapeutic application, 2017–2024 (USD bILLION)
TABLE 188          china: ACTIVE PHARMACEUTICAL INGREDIENTS Market, by type, 
2017–2024 (USD BILLION)
TABLE 189          china: active pharmaceutical ingredients Market, by type of manufacturer, 2017–2024 (USD bILLION) 178
TABLE 190          china: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2017–2024 (USD bILLION)
TABLE 191          china: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017–2024 (USD bILLION)
TABLE 192          china: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS,  2017–2024 (USD bILLION)
TABLE 193          china: synthetic Active pharmaceutical ingredients Market, by type,  2017–2024 (USD bILLION)
TABLE 194          china: biotech Active pharmaceutical ingredients Market,
by type,  2017–2024 (USD bILLION)
TABLE 195          china: Active pharmaceutical ingredients Market, by type of drug,  2017–2024 (USD bILLION)
TABLE 196          china: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 
2017–2024 (USD bILLION)
TABLE 197          china: Active pharmaceutical ingredients Market, by therapeutic application, 2017–2024 (USD bILLION)
TABLE 198          India: ACTIVE PHARMACEUTICAL INGREDIENTS Market, by type, 
2017–2024 (USD BILLION)
TABLE 199          India: active pharmaceutical ingredients Market, by type of manufacturer, 2017–2024 (USD BILLION) 182
TABLE 200          India: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2017–2024 (USD BILLION)
TABLE 201          India: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS,  2017–2024 (USD BILLION)
TABLE 202          India: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS,  2017–2024 (USD BILLION)
TABLE 203          India: synthetic Active pharmaceutical ingredients Market, by type,  2017–2024 (USD BILLION)
TABLE 204          India: biotech Active pharmaceutical ingredients Market, by type,  2017–2024 (USD BILLION)
TABLE 205          India: Active pharmaceutical ingredients Market, by type of drug,  2017–2024 (USD BILLION)
TABLE 206          India: Active pharmaceutical ingredients Market, by Potency, 
2017–2024 (USD BILLION)
TABLE 207          India: Active pharmaceutical ingredients Market, by therapeutic application, 2017–2024 (USD BILLION)
TABLE 208          south korea: ACTIVE PHARMACEUTICAL INGREDIENTS Market, 
by type, 2017–2024 (USD BILLION)
TABLE 209          south korea: active pharmaceutical ingredients Market,
by type of manufacturer, 2017–2024 (USD BILLION)
TABLE 210          south korea: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 
2017–2024 (USD BILLION)
TABLE 211          south korea: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017–2024 (USD BILLION)
TABLE 212          south korea: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017–2024 (USD BILLION)
TABLE 213          south korea: synthetic Active pharmaceutical ingredients Market, 
by type, 2017–2024 (USD BILLION)
TABLE 214          south korea: biotech Active pharmaceutical ingredients Market,
by type, 2017–2024 (USD BILLION)
TABLE 215          south korea: Active pharmaceutical ingredients Market,
by type of drug, 2017–2024 (USD BILLION)
TABLE 216          south korea: Active pharmaceutical ingredients Market,
by POTENCY,  2017–2024 (USD BILLION)
TABLE 217          south korea: Active pharmaceutical ingredients Market,
by therapeutic application, 2017–2024 (USD BILLION)
TABLE 218          RoA: ACTIVE PHARMACEUTICAL INGREDIENTS Market, by type, 
2017–2024 (USD BILLION)
TABLE 219          RoA: active pharmaceutical ingredients Market, by type of manufacturer, 2017–2024 (USD BILLION) 191
TABLE 220          RoA: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2017–2024 (USD BILLION)
TABLE 221          RoA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 
2017–2024 (USD BILLION)
TABLE 222          RoA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS,  2017–2024 (USD BILLION)
TABLE 223          RoA: synthetic Active pharmaceutical ingredients Market, by type,  2017–2024 (USD BILLION)
TABLE 224          RoA: biotech Active pharmaceutical ingredients Market, by type, 
2017–2024 (USD BILLION)
TABLE 225          RoA: Active pharmaceutical ingredients Market, by type of drug, 
2017–2024 (USD BILLION)
TABLE 226          RoA: Active pharmaceutical ingredients Market, by POTENCY, 
2017–2024 (USD BILLION)
TABLE 227          RoA: Active pharmaceutical ingredients Market, by therapeutic application, 2017–2024 (USD BILLION)
TABLE 228          RoW: ACTIVE PHARMACEUTICAL INGREDIENTS Market,  by type,
2017–2024 (USD BILLION)
TABLE 229          RoW: active pharmaceutical ingredients Market, by type of manufacturer, 2017–2024 (USD BILLION) 196
TABLE 230          RoW: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2017–2024 (USD BILLION)
TABLE 231          RoW: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 
2017–2024 (USD BILLION)
TABLE 232          RoW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS,  2017–2024 (USD BILLION)
TABLE 233          RoW: synthetic Active pharmaceutical ingredients Market, 
by type, 2017–2024 (USD BILLION)
TABLE 234          RoW: biotech Active pharmaceutical ingredients Market, by type,  2017–2024 (USD BILLION)
TABLE 235          RoW: Active pharmaceutical ingredients Market, by type
of drug,  2017–2024 (USD BILLION)
TABLE 236          RoW: Active pharmaceutical ingredients Market, by POTENCY, 
2017–2024 (USD BILLION)
TABLE 237          RoW: Active pharmaceutical ingredients Market, by therapeutic  application, 2017–2024 (USD BILLION)
TABLE 238          Active Pharmaceutical Ingredients market player ranking, 2018
TABLE 239          product Launches, 2016–2018
TABLE 240          Expansions, 2016–2018
TABLE 241          Acquisitions, 2015–2018
TABLE 242          Other strategies, 2015–2018
TABLE 243          EXCHANGE RATE (UTILIZED FOR THE CONVERSION OF EUR TO USD)
TABLE 244          EXCHANGE RATE (UTILIZED FOR THE CONVERSION OF GBP TO USD)
TABLE 245          exchange rates (utilized for the conversion of chf to USD)

FIGURE 1            APIs: market segmentation
FIGURE 2            research design
FIGURE 3            breakdown of primary interviews
FIGURE 4            bottom-up approach   36
FIGURE 5            top-down approach
FIGURE 6            data triangulation methodology
FIGURE 7            active pharmaceutical ingredients market, by type, 
2019 vs. 2024 (USD billion)
FIGURE 8            active pharmaceutical ingredients market, by type of manufacturer, 2019 Vs. 2024
FIGURE 9            Active pharmaceutical ingredients market, by type of synthesis, 
2019 Vs. 2024
FIGURE 10          biotech active pharmaceutical ingredients market, by product, 
2019 vs. 2024
FIGURE 11          Active pharmaceutical ingredients market, by therapeutic application, 2019 Vs. 2024
FIGURE 12          Geographical snapshot of the active pharmaceutical
ingredients Market
FIGURE 13          increasing incidence of chronic diseases and growing importance of generics are driving market growth
FIGURE 14          generic APIs TO grow at the highest CAGR from 2019 to 2024
FIGURE 15          merchant api manufacturers segment to register the highest growth during the forecast period   45
FIGURE 16          oncology segment to grow at the highest CAGR during the forecast period
FIGURE 17          prescription drugs to command the largest market share in 2019
FIGURE 18          China to witness the highest growth rate during the forecast period
FIGURE 19          Active Pharmaceutical Ingredients market: drivers, restraints, opportunities, and challenges
FIGURE 20          INNOVATIVE Active pharmaceutical ingredients SEGMENT to dominate thE market in 2019
FIGURE 21          captive manufacturerS SEGMENT to dominate thE market in 2019
FIGURE 22          synthetic apis to dominate the ACTIVE PHARMACEUTICAL INGREDIENTS market during the forecast period
FIGURE 23          active pharmaceutical ingredients MARKET, by type of drug
FIGURE 24          LOW-TO-MODERATE SEGMENT TO DOMINATE THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, IN 2019
FIGURE 25          COMMUNICABLE diseases to dominate thE active pharmaceutical ingredients market in 2019
FIGURE 26          NORTH AMERICA: MARKET SNAPSHOT
FIGURE 27          Europe: MARKET SNAPSHOT
FIGURE 28          Expansions—key growth strategy adopted by MARKET players from 2015 to October 2018
FIGURE 29          competitive leadership mapping of the Active Pharmaceutical Ingredients market
FIGURE 30          pfizer, inc.: Company snapshot (2017)
FIGURE 31          NOVARTIS AG: company snapshot (2017)
FIGURE 32          sanofi: company snapshot (2017)
FIGURE 33          BOEHRINGER INGELHEIM: company snapshot (2017)
FIGURE 34          BRISTOL-MYERS SQUIBB: company snapshot (2017)
FIGURE 35          teva pharmaceutical industries ltd.: Company snapshot (2017)
FIGURE 36          ELI LILLY and company: Company snapshoT (2017)
FIGURE 37          GLAXOSMITHKLINE PLC: company snapshot (2017)
FIGURE 38          MERCK & CO., INC.: company snapshot (2017)
FIGURE 39          abbvie inc.: Company snapshot (2017)
FIGURE 40          F. HOFFMANN-LA ROCHE: company snapshot (2017)
FIGURE 41          AstraZeneca: company snapshot (2017)

当レポートのプレスリリースは発行されておりません。